NR1H4 and metabolic dysfunction-associated steatotic liver disease: The first clinically available FXR agonist obeticholic acid (OCA) improved liver enzymes and insulin sensitivity in patients with NAFLD and type II diabetes [15], with a significant histological improvement of NASH and a reduction of liver fibrosis in the consecutive phase IIb trial [16].